Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 7/20 | 0.42 |
| ▸ | CMA1 | P23946 | 6/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688943 | 0.81 | MAPT (0.47) | EPHX2MEN1KMT2AMLYCDHDAC3 | |
| SCHEMBL21335533 | 0.80 | MAPT (0.49) | EPHX2MEN1KMT2AMLYCDHDAC3 | |
| SCHEMBL1877453 | 0.80 | POLB (0.64) | EPHX2MEN1KMT2ACTSGCMA1 | |
| SCHEMBL1879427 | 0.79 | HDAC3 (0.56) | EPHX2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL7826783 | 0.77 | CTSG (0.47) | EPHX2MEN1KMT2ACTSGCMA1 | |
| SCHEMBL507273 | 0.77 | EPHX2 (0.55) | EPHX2MEN1KMT2ACTSGCMA1 | |
| SCHEMBL5008089 | 0.77 | MEN1 (0.49) | EPHX2MEN1KMT2ACTSGCMA1 | |
| SCHEMBL689307 | 0.77 | HDAC3 (0.58) | MGLLMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL7835600 | 0.76 | CTSG (0.46) | EPHX2MGLLMEN1KMT2ACTSG | |
| SCHEMBL22265515 | 0.75 | L3MBTL1 (0.68) | EPHX2MGLLMEN1KMT2AMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939688-B2 | Reacting N-alkylcarboxamides or ammonium salts of carboxylic acids in the presence of alkylamines or ammonium salts of in presence of 2,4,6-substituted 1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide and/or a base | ARCHIMICA GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20080242884-A1 | Process for Preparing Nitriles by Elimination Reactions | EUTICALS GMBH (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242884-A1 | Process for Preparing Nitriles by Elimination Reactions | CBR1, CBR3, PHOSPHO1 | EPHX2 607/4885MGLL 3551/4885MEN1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.